Know Cancer

or
forgot password

Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC


N/A
18 Years
N/A
Not Enrolling
Both
Multiple Myeloma and Plasma Cell Neoplasm

Thank you

Trial Information

Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC


OBJECTIVES:

Primary

- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex
vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs)
in peripheral blood and bone marrow samples from patients with multiple myeloma.

Secondary

- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo
using interferon γ release and CD3/CD28 stimulation.

OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory
studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex
vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell
antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function
of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting
T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T
cells are expanded ex vivo using anti CD3/CD28 beads.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of multiple myeloma

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Percentage of myeloma-specific T cells ex vivo expanded using flow cytometry

Outcome Time Frame:

Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.

Safety Issue:

No

Principal Investigator

Zaid Al-Kadhimi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Barbara Ann Karmanos Cancer Institute

Authority:

United States: Food and Drug Administration

Study ID:

CDR0000597015

NCT ID:

NCT00897910

Start Date:

April 2008

Completion Date:

Related Keywords:

  • Multiple Myeloma and Plasma Cell Neoplasm
  • stage I multiple myeloma
  • stage II multiple myeloma
  • stage III multiple myeloma
  • refractory multiple myeloma
  • Neoplasms
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Plasmacytoma

Name

Location

Barbara Ann Karmanos Cancer InstituteDetroit, Michigan  48201